38 results on '"Miners, John O."'
Search Results
2. Response to in vitro and physiologically‐based pharmacokinetic assessment of the drug–drug interaction potential of canagliflozin
3. Advances in drug metabolism and pharmacogenetics research in Australia
4. Scaling factors for the in vitro–in vivo extrapolation (IV–IVE) of renal drug and xenobiotic glucuronidation clearance
5. Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT)
6. Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity
7. The glycosidation of xenobiotics and endogenous compounds: Versatility and redundancy in the UDP glycosyltransferase superfamily
8. Homodimerization of UDP-glucuronosyltransferase 2B7 (UGT2B7) and identification of a putative dimerization domain by protein homology modeling
9. Whatʼs in a name?
10. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment
11. Differential disposition of intra-renal generated and preformed glucuronides: studies with 4-methylumbelliferone and 4-methylumbelliferyl glucuronide in the filtering and nonfiltering isolated perfused rat kidney
12. Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity
13. Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: Inhibition by NSAIDs
14. Macrolide–theophylline interactions: no role for the inhibition of cytochrome P4501A2
15. In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway
16. Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants
17. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination
18. Quality of requests for serum digoxin concentrations: experience from an Australian Regional Health Service
19. Glucuronidation of fenamates: Kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7
20. Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation
21. Nonselective nonsteroidal anti-inflammatory drugs and increased cardiovascular events: emotional stress could be the explanation
22. Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymes
23. Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime?
24. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid
25. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: Pitfalls and promises
26. Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation
27. S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen
28. Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7
29. EVOLUTION OF DRUG METABOLISM: HITCHHIKING THE TECHNOLOGY BANDWAGON
30. In vitro–in vivo correlations for drugs eliminated by glucuronidation: Investigations with the model substrate zidovudine
31. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes
32. The xenobiotic inhibitor profile of cytochrome P4502C8
33. Nonspecific binding of drugs to human liver microsomes
34. Cytochrome P450 isoform selectivity in human hepatic theobromine metabolism
35. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
36. Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo
37. New Uses for Allopurinol
38. Drug Interactions Involving Aspirin (Acetylsalicylic Acid) and Salicylic Acid
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.